Cargando…

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: de Lucas, Raúl, García-Millán, Cristina, Pérez-Davó, Azahara, Moreno, Esther, Redondo, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406490/
https://www.ncbi.nlm.nih.gov/pubmed/30700045
http://dx.doi.org/10.3390/children6020017
_version_ 1783401316237705216
author de Lucas, Raúl
García-Millán, Cristina
Pérez-Davó, Azahara
Moreno, Esther
Redondo, Pedro
author_facet de Lucas, Raúl
García-Millán, Cristina
Pérez-Davó, Azahara
Moreno, Esther
Redondo, Pedro
author_sort de Lucas, Raúl
collection PubMed
description Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy, a prospective, open-label, and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index, and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent’s Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, a regular use of this new formulation can reduce the risk of relapse and extend the steroid-free treatment periods.
format Online
Article
Text
id pubmed-6406490
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64064902019-03-13 New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis de Lucas, Raúl García-Millán, Cristina Pérez-Davó, Azahara Moreno, Esther Redondo, Pedro Children (Basel) Communication Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy, a prospective, open-label, and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index, and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent’s Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, a regular use of this new formulation can reduce the risk of relapse and extend the steroid-free treatment periods. MDPI 2019-01-29 /pmc/articles/PMC6406490/ /pubmed/30700045 http://dx.doi.org/10.3390/children6020017 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
de Lucas, Raúl
García-Millán, Cristina
Pérez-Davó, Azahara
Moreno, Esther
Redondo, Pedro
New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
title New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
title_full New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
title_fullStr New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
title_full_unstemmed New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
title_short New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
title_sort new cosmetic formulation for the treatment of mild to moderate infantile atopic dermatitis
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406490/
https://www.ncbi.nlm.nih.gov/pubmed/30700045
http://dx.doi.org/10.3390/children6020017
work_keys_str_mv AT delucasraul newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis
AT garciamillancristina newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis
AT perezdavoazahara newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis
AT morenoesther newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis
AT redondopedro newcosmeticformulationforthetreatmentofmildtomoderateinfantileatopicdermatitis